MX2024010982A - Antibióticos anti-ilt2 y usos de esto - Google Patents
Antibióticos anti-ilt2 y usos de estoInfo
- Publication number
- MX2024010982A MX2024010982A MX2024010982A MX2024010982A MX2024010982A MX 2024010982 A MX2024010982 A MX 2024010982A MX 2024010982 A MX2024010982 A MX 2024010982A MX 2024010982 A MX2024010982 A MX 2024010982A MX 2024010982 A MX2024010982 A MX 2024010982A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- ilt2
- transcript
- polypeptides
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268945P | 2022-03-07 | 2022-03-07 | |
| PCT/US2023/063821 WO2023172890A2 (en) | 2022-03-07 | 2023-03-07 | Anti-ilt2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010982A true MX2024010982A (es) | 2025-02-10 |
Family
ID=87935886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010982A MX2024010982A (es) | 2022-03-07 | 2024-09-06 | Antibióticos anti-ilt2 y usos de esto |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250109201A1 (https=) |
| EP (1) | EP4490196A2 (https=) |
| JP (1) | JP2025508075A (https=) |
| KR (1) | KR20250004950A (https=) |
| CN (1) | CN119365487A (https=) |
| AU (1) | AU2023231622A1 (https=) |
| CA (1) | CA3254318A1 (https=) |
| IL (1) | IL315487A (https=) |
| MX (1) | MX2024010982A (https=) |
| WO (1) | WO2023172890A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025059304A2 (en) * | 2023-09-12 | 2025-03-20 | Agenus Inc. | Methods of treating cancer using ilt2 antibodies and combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CA2541360A1 (en) * | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| EP3580239A4 (en) * | 2017-02-09 | 2021-07-28 | Bluefin Biomedicine, Inc. | ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES |
| MX2021015024A (es) * | 2020-04-28 | 2022-01-18 | Univ Rockefeller | Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos. |
| AU2021265801B2 (en) * | 2020-05-01 | 2026-04-02 | Ngm Biopharmaceuticals, Inc. | ILT-binding agents and methods of use thereof |
-
2023
- 2023-03-07 AU AU2023231622A patent/AU2023231622A1/en active Pending
- 2023-03-07 EP EP23767599.6A patent/EP4490196A2/en active Pending
- 2023-03-07 WO PCT/US2023/063821 patent/WO2023172890A2/en not_active Ceased
- 2023-03-07 CA CA3254318A patent/CA3254318A1/en active Pending
- 2023-03-07 CN CN202380038440.3A patent/CN119365487A/zh active Pending
- 2023-03-07 KR KR1020247032336A patent/KR20250004950A/ko active Pending
- 2023-03-07 IL IL315487A patent/IL315487A/en unknown
- 2023-03-07 JP JP2024553452A patent/JP2025508075A/ja active Pending
-
2024
- 2024-09-06 US US18/827,368 patent/US20250109201A1/en active Pending
- 2024-09-06 MX MX2024010982A patent/MX2024010982A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3254318A1 (en) | 2023-09-14 |
| IL315487A (en) | 2024-11-01 |
| WO2023172890A3 (en) | 2023-10-19 |
| AU2023231622A1 (en) | 2024-09-26 |
| US20250109201A1 (en) | 2025-04-03 |
| KR20250004950A (ko) | 2025-01-09 |
| WO2023172890A2 (en) | 2023-09-14 |
| EP4490196A2 (en) | 2025-01-15 |
| CN119365487A (zh) | 2025-01-24 |
| JP2025508075A (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| MX2022001049A (es) | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos. | |
| MX2020009394A (es) | Anticuerpos anti-cd73 y métodos de uso de los mismos. | |
| MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| MX2021011696A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
| MX2021014952A (es) | Molecula de union especifica para cd73 y uso de la molecula de union. | |
| CO2020010269A2 (es) | Variantes fc con unión mejorada a fcrn y semivida prolongada | |
| CL2008001814A1 (es) | Anticuerpos anti-factor de crecimiento 1 y 2 semejantes a insulina (igf-1, igf-2); molecula de adn que los codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
| CO6761352A2 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| CO2022001977A2 (es) | Anticuerpos anti-cd96 y sus métodos de uso | |
| CO2025017440A2 (es) | Anticuerpos de dominio único modificados | |
| MX2024010982A (es) | Antibióticos anti-ilt2 y usos de esto | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| MX2023012707A (es) | Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos. | |
| BR112017022076A2 (pt) | fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas | |
| PE20190967A1 (es) | Aislados modificados de streptomyces fungicidicus y su uso | |
| WO2025122587A3 (en) | Anti-ly6k antibodies and methods of use | |
| WO2024073474A3 (en) | Anti-pla2g10 antibodies and methods of use | |
| EA202192299A1 (ru) | Библиотеки вариантных нуклеиновых кислот для оптимизации антител |